Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 20Lymphoma 6Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphomatoid Papulosis 3Lymphoma, Large-Cell, Anaplastic 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Immunoblastic Lymphadenopathy 2Hematologic Diseases 2Enteropathy-Associated T-Cell Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

mogamulizumab 4Specimen Handling 3Immunoglobulin G 3Disulfides 3Cyclophosphamide 3Biopsy 3pembrolizumab 2fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Photopheresis 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mycophenolic Acid 2Magnetic Resonance Spectroscopy 2Busulfan 2Blood Specimen Collection 2talimogene laherparepvec 1magrolimab 1duvelisib 1durvalumab 1Vincristine 1Valganciclovir 1Urine Specimen Collection 1Transplantation 1Therapeutics 1Sirolimus 1Radiotherapy 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sezary Syndrome × Brentuximab Vedotin × 1 year × Clear all
NCT03587844 2026-04-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
58 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡